In a nutshell Researchers developed personalized cancer vaccines for nine high-risk kidney cancer patients, with all participants remaining cancer-free after nearly three years of follow-up – a ...

Vaccines generated using the cells left over after tumour removal surgery could help to keep patients from redeveloping ...

Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear ...

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successf ...

Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a ...

During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on ...

A phase 1 study of a personalized cancer vaccine demonstrated antitumor immunity in all treated patients with resected renal ...

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

All patients involved in the phase 1 trial of a personalized cancer vaccine for high-risk stage III/IV kidney cancer showed a successful anticancer immune response.

Researchers have published findings from the phase 2 LITESPARK-003 study of patients with previously untreated advanced clear ...

In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated ...